Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Treating Refractory Hematological Malignancies- Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
Publication Date Sep 2013
Publisher MP ADVISORS
Product Type Report
Single User License help $ 2500.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts.  The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.
Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report.  Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report.  This report is built using primary and secondary research data and in-house proprietary database.

Reasons to buy the report:
Useful for investors, Scientists, Business development managers of Pharma companies with focus in oncology to address the following-
What are the opportunities or new approaches to be deployed in the R&D of the company?
List of validated and new targets
In-licensing opportunities – Is the way to go forward and be in the race?
Commercial opportunity and companies’ valuation.

Key points discussed in the report:
Overview of the Disease and Unmet need
Drugs in the pipeline: NDMM & RRMM – Mechanism of Action (MoA) and Clinical Stage of development
Comparative Clinical data of Late-stage Pipeline in RRMM and NDDM
Ongoing Clinical trial Details of Key Drugs in Pipeline
Key milestones
MPA view on the Future of the drugs in the late-stage pipeline
Launch Timeline and Commercial Opportunity of Late-stage pipeline
M&A and Licensing deals in the last 5 years
In-licensing and/or M&A Opportunity
Detailed Company analysis includes Clinical data of drugs, Milestones, and Valuation – Amgen (AMGN), Celgene (CELG), and MorphoSys (MOR)

Table of Contents
1. Executive Summary
2. Investment Drivers of The Select Companies Covered
3. Multiple Myeloma (MM)
3.1 Disease Overview
3.2 Current Standard of Care
3.2.1 Relapsed and/or Refractory Multiple Myeloma (RRMM)
a  Competitive landscape – RRMM
b Data Comparison – RRMM
3.2.2 Newly Diagnosed Multiple Myeloma (NDMM)
a Competitive landscape – NDMM
b Data Comparison – NDMM
4. Novel Targets including Monoclonal Antibodies And Small Molecules Offer In-Licensing Opportunity
4.1 Overview of Targets involved
4.2 Late-stage pipeline – Small Molecules
4.2.1 Kyprolis (carfilzomib)
4.2.2 POMALYST / IMNOVID (pomalidomide)
4.2.3 Ixazomib (MLN9708)
4.2.4 Panobinostat
4.2.5 Obatoclax
4.2.6 SNS01-T
4.2.7 Oprozomib
4.3 Late-stage pipeline – Monoclonal Antibodies
4.3.1 Elotuzumab
4.3.2 Siltuximab
4.3.3 Daratumumab
4.3.4 MOR202
5. Ongoing Clinical Trial Details of Key Drugs in the Pipeline
6. Key Milestones
7. MPA View on the Future of the Drugs in the Late-Stage
pipeline
7.1 Launch Timeline and Commercial Opportunity of Late-stage
Pipeline (RRMM and NDMM)
7.2 Drivers of M&A / Licensing Deals in MM
7.2.1 Select M&A Deals in Last 5 Years – 2007 to 2012
7.2.2 Select Licensing Deals in Last 5 Years – 2007 to 2012
7.2.3 M&A and Licensing Deals Opportunity
8. Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and Valuation)
8.1 Amgen (AMGN, Post-acquisition of Onyx pharma)
8.1.1 Investment Drivers
8.1.2 Longer-term growth
a Acquisition of Onyx and its pipeline discussion
8.1.3 Late-stage pipeline
a Denosumab label expansion
b AMG 145 – Data presented at ESC 2013 and its comparison
with REGN/SNY’s REGN727/SAR236553
c Collaboration agreement with Servier
d Talimogene laherparepvec (T-VEC)
e Trebananib (AMG 386)
8.1.4 Opportunity in Emerging market and Expansion in other
Geographies
8.1.5 Key Milestones
8.1.6 NPV Valuation
8.2 Celgene (CELG)
8.2.1 Investment Drivers
8.2.2 Growth from Marketed products and Label expansion
a Revlimid – Geographic expansion and Generic threat after 2019
b Pomalyst – Current market scenario and competition to Kyprolis
c ABRAXANE – Label expansion
d Vidaza – Oral formulation and Generic entry in the US market
e Inflammation pipeline to start contributing to sales by 2014
f Novel Early stage products
8.2.3 Key Milestones
8.2.4 NPV Valuation
8.3 MorphoSyS
8.3.1 Investment Drivers
8.3.2 Recent Alliances
a. MOR / CELG for MOR202 (PhI/II, RRMM, anti-CD38 mAb)
b. MOR/ GSK for MOR103 (PhII, RA, anti-GM-CSF mAb)
8.3.3 Clinical Data from partnered pipeline products in 2H13 and Beyond
a. Bimagrumab (BYM338, PhII, COPD, Cancer, ActRIIB, sIBM)
b. BHQ880 (PhII, MM, anti-DKK-1 mAb)
c. Gantenerumab (IgG, PhIII, Alzheimer’s disease)
8.3.4 Other Partnered programs
8.3.5 Novel proprietary technology platforms
8.3.6 Key Milestones
8.3.7 NPV Valuation

Title Date Price
2012 Deep Research Report on China Human Albumin Industry
By QYResearch
2012 Deep Research Report on China Human Albumin Industry was professional and depth research report on China Human Albumin industry. This report has firstly introduced Human Albumin definition classi ...Read More
Nov 2012 $2000.00
2013 Deep Research Report on Global and China Human Coagulation Factor Ⅷ Industry
By QYResearch
2013 Deep Research Report on Global and China Human Coagulation Factor Ⅷ Industry is a professional and depth research report on Global and China Human Coagulation Factor Ⅷ industry. This ...Read More
Mar 2013 $2200.00
2014 Deep Research Report on Global and China Glutamate Dehydrogenase Industry
By QYResearch
<2014 Deep Research Report on Global and China Glutamate Dehydrogenase Industry> was professional and depth research report on Global and China Glutamate Dehydrogenase industry. The report first ...Read More
May 2014 $2200.00
2014 Deep Research Report on Global And China Nucleotide Industry
By QYResearch
<2014 Deep Research Report on Global And China Nucleotide Industry> was professional and depth research report on Global and China Nucleotide Industry. The report firstly introduced Nucleotide b ...Read More
Jan 2014 $2200.00
2014 Deep Research Report on Global And China Pectinase Industry
By QYResearch
<2014 Deep Research Report on Global And China Pectinase Industry> was professional and depth research report on Global and China Pectinase industry. The report firstly introduced Pectinase basi ...Read More
Mar 2014 $2200.00
2014 Deep Research Report on Global and China Xylose Industry
By QYResearch
<2014 Deep Research Report on Global and China Xylose Industry> was professional and depth research report on Global and China Xylose industry. The report firstly introduced Xylose basic informa ...Read More
Jun 2014 $2200.00
Argentina Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and Others
By GlobalData
Argentina Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and OthersSummaryGlobalData’s new report, ...Read More
Nov 2012 $2500.00
Asia-Pacific Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and Others
By GlobalData
Asia-Pacific Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and OthersSummaryGlobalData’s new repor ...Read More
Nov 2012 $3500.00
Australia Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and Others
By GlobalData
Australia Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Biomaterials and Crowns and Bridges and OthersSummaryGlobalData’s new report, ...Read More
Nov 2012 $2500.00
Austria Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Dental Biomaterials, Crowns and Bridges and Others
By GlobalData
Austria Dental Devices Market Outlook to 2018 - CAD/CAM Dental Systems, Dental Chairs and Equipment, Dental Implants, Dental Biomaterials, Crowns and Bridges and OthersSummaryGlobalData’s new report ...Read More
Nov 2012 $2500.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z